Memory-like differentiation enhances NK cell responses against colorectal cancer

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-05-07 DOI:10.1080/2162402x.2024.2348254

Nancy D. Marin, Michelle Becker-Hapak, Wilbur M. Song, Quazim A. Alayo, Lynne Marsala, Naomi Sonnek, Melissa M. Berrien-Elliott, Mark Foster, Jennifer A. Foltz, Jennifer Tran, Pamela Wong, Celia C. Cubitt, Patrick Pence, Kimberly Hwang, Alice Y. Zhou, Miriam T. Jacobs, Timothy Schappe, David A. Russler-Germain, Ryan C. Fields, Matthew A. Ciorba, Todd A. Fehniger

引用次数: 0

Abstract

Metastatic (m) colorectal cancer (CRC) is an incurable disease with a poor prognosis and thus remains an unmet clinical need. Immune checkpoint blockade (ICB)-based immunotherapy is effective for m...

查看原文本刊更多论文

记忆样分化可增强 NK 细胞对结直肠癌的反应

转移性结直肠癌（CRC）是一种无法治愈的疾病，预后较差，因此仍是一项尚未满足的临床需求。以免疫检查点阻断（ICB）为基础的免疫疗法对转移性结直肠癌（CRC）有很好的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.